SCHEMBL23453734

SCHEMBL23453734

Cc1snc(C(=O)O)c1Nc1cccc(-c2ccc(C#N)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 3/20 0.43
▸ CSF1R P07333 2/20 0.43
▸ ABCG2 Q9UNQ0 2/20 0.40
▸ ABCB1 P08183 1/20 0.40
▸ ABCC1 P33527 1/20 0.40
▸ PIN1 Q13526 1/20 0.40
▸ PSEN1 P49768 1/20 0.40
▸ PSEN2 P49810 1/20 0.40
▸ APH1B Q8WW43 1/20 0.40
▸ NCSTN Q92542 1/20 0.40
▸ APH1A Q96BI3 1/20 0.40
▸ PSENEN Q9NZ42 1/20 0.40
▸ PTPN11 Q06124 2/20 0.39
▸ KAT6A Q92794 1/20 0.39
▸ CFTR P13569 1/20 0.39
▸ KCNH2 Q12809 1/20 0.37
▸ SCN10A Q9Y5Y9 1/20 0.37
▸ XDH P47989 1/20 0.37
▸ SLC22A12 Q96S37 1/20 0.37
▸ MARK3 P27448 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23453756 0.89 CSF1R (0.40) CSF1RABCG2ABCB1KCNH2SCN10A
SCHEMBL22609280 0.85 GSK3A (0.42) CSF1RABCG2GSK3A
SCHEMBL23453703 0.80 ALDH1A1 (0.47) SYKCSF1RABCG2ABCB1ABCC1
SCHEMBL23453745 0.80 HAO2 (0.47) SYKCSF1RABCG2ABCB1ABCC1
SCHEMBL22609308 0.79 FABP5 (0.43) XDHGSK3AMAOAMAOB
SCHEMBL22609306 0.77 RAPGEF4 (0.48) ABCG2ABCB1ABCC1PTPN11
SCHEMBL23453725 0.75 KDM4E (0.43) GSK3A
SCHEMBL22609323 0.73 SYK (0.45) SYKCSF1RABCG2ABCB1ABCC1
SCHEMBL22609261 0.70 KDM4E (0.46) GSK3A
SCHEMBL15158542 0.68 ABCG2 (0.59) SYKABCG2ABCB1ABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS SYK 1131/4885CSF1R 1887/4885ABCG2 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback